New Operations Manager at Biovica

Uppsala, December 5, 2017. Biovica has appointed Adam Germunder as new Operations Manager. Adams responsibilities include to build and secure the company’s production capabilities and ensure that they meet regulatory requirements in preparation for the commercialization of DiviTum®.

 

Adam has experience in production management and process development. He has worked, among other things, to develop and implement new production methods in ISO13485-certified medical technology companies. Adams previous professional experiences include roles such as Production manager at Fiomi Diagnostics where he was responsible for the production processes and from the company Fresenius Kabi. His experience includes planning and building scalable production environments for diagnostic products and ensuring compliance with high regulatory requirements from, among others, the FDA.

"We are very pleased to welcome Adam to our management team and securing important experiences from production, upscaling, and ensuring that production processes meet high regulatory requirements such as the FDA. This experience is very important to Biovica for the forthcoming commercialization of our product DiviTum. DiviTum is the answer for a clear diagnostic need by evaluating the effect of cancer treatments, and is expected to provide great values for patients and society. " - Anders Rylander, CEO Biovica

 

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email:  anders.rylander@biovica.com

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more:  www.biovica.com

Tags:

About Us

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

Subscribe

Media

Media

Documents & Links